TSPAN4-positive migrasome derived from retinal pigmented epithelium cells contributes to the development of proliferative vitreoretinopathy

J Nanobiotechnology. 2022 Dec 9;20(1):519. doi: 10.1186/s12951-022-01732-y.

Abstract

Background: Proliferative vitreoretinopathy (PVR) is a blind-causing disease initiated by the activation of retinal pigmented epithelium (RPE) primarily induced by TGF-β families. Migrasome is a recently discovered type of extracellular vesicle related to cell migration.

Results: Here, we used ex vivo, in vitro, and in vivo models, to investigate the characteristics and functions of migrasomes in RPE activation and PVR development. Results indicated that the migrasome marker tetraspanin-4 (TSPAN4) was abundantly expressed in human PVR-associated clinical samples. The ex vivo model PVR microenvironment is simulated by incubating brown Norway rat RPE eyecups with TGF-β1. Electron microscope images showed the formation of migrasome-like vesicles during the activation of RPE. Further studies indicated TGF-β1 increased the expression of TSPAN4 which results in migrasome production. Migrasomes can be internalized by RPE and increase the migration and proliferation ability of RPE. Moreover, TSPAN4-inhibited RPE cells are with reduced ability of initiating experimental PVR. Mechanically, TSPAN4 expression and migrasome production are induced through TGF-β1/Smad2/3 signaling pathway.

Conclusion: In conclusion, migrasomes can be produced by RPE under PVR microenvironment. Migrasomes play a pivotal role in RPE activation and PVR progression. Thus, targeting TSPAN4 or blocking migrasome formation might be a new therapeutic method against PVR.

Keywords: Epithelial–mesenchymal transition; Migrasome; Proliferative vitreoretinopathy; Retinal pigmented epithelium; tetraspanin4.

MeSH terms

  • Cell Movement
  • Cells, Cultured
  • Epithelial-Mesenchymal Transition / physiology
  • Epithelium
  • Humans
  • Retinal Pigment Epithelium
  • Transforming Growth Factor beta1* / metabolism
  • Vitreoretinopathy, Proliferative* / drug therapy
  • Vitreoretinopathy, Proliferative* / metabolism

Substances

  • Transforming Growth Factor beta1